IDEAYA Biosciences 3Q 2026: Revenue $10.2M, Net loss $125.7M, EPS $(1.22) — 10-Q Summary

What happened

IDEAYA Biosciences reported third-quarter 2026 revenue of $10.2 million, down from $207.8 million a year earlier, which had included upfront Servier license revenue. It posted a net loss of $125.7 million versus net income of $119.2 million, and diluted EPS was $(1.22) versus $1.33.

Confirmed

Global impact / market context

The revenue drop is mostly a comparison effect, since last year's quarter included a large one-time license payment. The $125.7 million net loss shows the company is spending heavily on research and trials, so its cash position and funding needs matter more than the headline revenue decline.

Analyst inference

Investors in drug developers often look past one-time license payments and focus on recurring revenue and trial progress. With no product sales yet contributing meaningfully, IDEAYA's value depends on regulatory filings like the darovasertib application and on how much cash the loss consumes.

Analyst inference

What to watch

1. IDEAYA submitted a new drug application for darovasertib in metastatic uveal melanoma under the FDA's Real-Time Oncology Review program, a faster review path, and data updates supported its potential across patient groups. Confirmed
2. The company closed enrollment in its Phase 3 neoadjuvant OptimUM-010 trial amid site and enrollment challenges, and launched the Phase 3 adjuvant OptimUM-011 trial with partner Servier. Confirmed
3. Watch the company's cash burn, which means how fast it spends cash, given the $125.7 million quarterly loss, and whether partner Hengrui starts its planned Phase 3 trial of IDE849 by year-end 2026. Analyst inference

Evidence

• Original source link unavailable